Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...

Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells ...

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

Shares of Viking Therapeutics VKTX rose nearly 8% on Friday after several third-party reports suggested that it was being ...

We recently published a list of 11 Best Performing Dow Stocks So Far in 2025. In this article, we are going to take a look at ...

The global Heart Failure Drugs Market is valued at $8.6 billion in 2024 and is projected to reach a value of $21.4 billion by 2035. This growth represents a Compound Annual Growth Rate (CAGR) of 12.1% ...

and obesity) and health factors (cholesterol, blood pressure, glucose control, and metabolic syndrome) that contribute to cardiovascular health. The AHA Heart Disease and Stroke Statistical Update ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Amgen Inc.

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...